Alaw nominates CDK4 inhibitor AL-433 as development candidate

June 1, 2026

Alaw Therapeutics Inc. has announced the nomination of AL-433, a selective, brain-penetrant CDK4 inhibitor, as a development candidate.

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for June 1, 2026.

TROP2 ADCs progress into first-line for lung, breast cancers

BioWorld

Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...

Illustration of antibodies and viral infection

New evidence links autoimmunity to long COVID symptoms

BioWorld

Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...

Liver with hepatitis viruses, blood cells

Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

BioWorld

GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...

Healthy (left) vs. cancerous bone marrow

BMS’ mezigdomide doubles PFS in multiple myeloma

BioWorld

Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...